---
title: "Compass Pathways says Phase 3 COMP006 study shows COMP360 psilocybin maintains benefit through week 26 in TRD"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291916719.md"
description: "Compass Pathways reported that its Phase 3 COMP006 study showed COMP360 psilocybin maintained benefits through week 26 in treatment-resistant depression. In the 25 mg arm, 39% achieved clinically meaningful MADRS reduction by week 6. The company is rolling out an FDA NDA submission, targeting final filing in Q4 2026, with a planned launch in H1 2027 pending approval and DEA rescheduling."
datetime: "2026-07-07T10:30:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291916719.md)
  - [en](https://longbridge.com/en/news/291916719.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291916719.md)
---

# Compass Pathways says Phase 3 COMP006 study shows COMP360 psilocybin maintains benefit through week 26 in TRD

-   Compass Pathways reported 26-week Phase 3 COMP006 data for COMP360 psilocybin in treatment-resistant depression, supporting rapid onset and durable benefit. \* In the 25 mg arm, 39% achieved a clinically meaningful MADRS reduction at week 6, with benefit maintained on average through week 26. \* Rolling FDA NDA submission is underway, with final submission targeted for Q4 2026. \* Launch is planned for the first half of 2027, contingent on FDA approval and subsequent DEA rescheduling. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260707713443) on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CMPS.US](https://longbridge.com/en/quote/CMPS.US.md)

## Related News & Research

- [Compass Pathways publishes investor presentation on COMP360 psilocybin program, FDA filing progress and launch plans](https://longbridge.com/en/news/294963906.md)
- [Compass Pathways grants new-hire inducement equity awards at USD 11.25 per share](https://longbridge.com/en/news/295021252.md)
- [CMPS: Q2 2026 net loss widened to $253.8M; Phase 3 TRD milestones achieved; cash runway into 2028](https://longbridge.com/en/news/294951377.md)
- [Climb Bio initiates Phase 2 CLYM116 trial in IgA nephropathy in Q3 2026](https://longbridge.com/en/news/295100999.md)
- [Compugen publishes corporate presentation on AI-driven immuno-oncology antibody pipeline](https://longbridge.com/en/news/294684055.md)